NYU Doctors Explain DCIS

The FDA approved a perioperative pembrolizumab regimen in head and neck squamous cell carcinoma, marking the first approval in this cancer type in 6 years.

In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.

UGN-102 has received FDA approval for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

The tyrosine kinase inhibitor taletrectinib has been approved for use in patients with ROS1-positive non-small cell lung cancer.

T-DXd led to an ORR of 59.4% vs 33.9% with chemo, regardless of biomarker status, in HR+, HER2-low metastatic breast cancer, per DESTINY-Breast06.